References
- Brown AE. Overview of fungal infections in cancer patients. Semin Oncol 1990;17(3 Suppl 6):2–5.
- Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970;49: 147–173.
- Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Chin Microbiol Infect Dis 1992;11: 99–109.
- Martino R, Subira M. Invasive fungal infections in hematol-ogy: new trends. Ann Hematol 2002;81:233–243.
- Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis 1994;7:456–462.
- EORTC. International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86(6 Pt 1):668–672.
- Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:9–35.
- Meyer RD. Current role of therapy with amphotericin B. Chin Infect Dis 1992;14\(Suppl. 1): 154 — 160.
- Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–771.
- Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001;322: 579–582.
- Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observation study. Clin Infect Dis 2003;36:943–951.
- Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002;132:455–458.
- Schneemann M, Bachli EB. Continuous infusion of ampho-tericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections? Clin Infect Dis 2004;38:303 —304.
- Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation, Swiss Med Wkly 2002;132:316–320.
- Nakase K, Yazaki A, Tamaki S, Tanigawa M, Tsuji K, Miyanishi E, Shiku H. Effect of direct infusion of antifungal agent on invasive pulmonary aspergillosis in a patient with acute leukaemia. J Infect Chemother 2002;8:106–108.
- Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new gold standard. Clin Infect Dis 2003;37:415–425.
- Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z et al. Invasive Fungal Infections Cooperative Group of the Eur-opean Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consen-sus. Clin Infect Dis 2002;34:7–14.
- Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabin° H. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005;11:101–108.
- Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.